📌 First meta-analysis on recompensation in decompensated cirrhosis
🔍 More common in viral etiologies & lower MELD
📉 Linked to lower risk of HCC & death
✅ A meaningful clinical endpoint

Read more here: https://ow.ly/tYnJ50YvNUo
#LiverTwitter @wong__yujun @BavenoCoop

📊 CHB patients on Peg-IFN:

✅ HBsAg decline at wk24 & baseline HBsAg best predict functional cure.
✅ HBV RNA & HBeAg levels (wk12/24) best predict HBeAg loss.

Guiding personalized therapy.
👥 @HenryEChang@asianliverctr

#Hepatology #HBV #LiverTwitter

👉 www.xiahepublishing.com/2310-8819/JC...

Predicting PEG-IFN response in hepatitis B: HBsAg decline at week 24 best predicts functional cure. For HBeAg loss, HBV RNA & HBeAg levels at week 12 are key. Better markers = tailored therapy. #HBV #HepatitisB #LiverTwitter

New expert consensus on inherited hyperbilirubinemia (Gilbert, Crigler-Najjar, etc.) now available. Led by Chinese Medical Association, it integrates latest advances to guide diagnosis & management. #LiverTwitter #Genetics #MedTwitter

👉https://xiahepublishing.com/2310-8819/JCTH-2025-00440

🚨Just 3 weeks away‼️
Join the VALDIG PSVD Meeting 2025 in Paris 🇫🇷

🗓️ Dec 4–5 @ CNAM
💳 Onsite €150 | 💻 Online FREE
👉 Organized by EURO-VALDIG NET & FILFOIE
🔗 Registration → app.evalandgo.com/f/325218/4qE...
📘 Updated program below 👇
#LiverTwitter

So excited to be in Washington DC for my first #TLM25 with wonderful colleagues!

A toast to you all with a delicious mocktail! Will see you around! Can’t wait!

#LiverTwitter @aasldnews.bsky.social

🚨Just one month away‼️
Join the VALDIG PSVD Meeting 2025 in Paris 🇫🇷

🗓️ Dec 4–5 @ CNAM
💳 Onsite €150 | 💻 Online FREE
👉 Organized by EURO-VALDIG NET & FILFOIE
🔗 Registration -> app.evalandgo.com/f/325218/4qE...
📘 Full program below 👇 #LiverTwitter

Important Deadlines for #BavenoVIII ‼️

💶 Early registration: 15 Dec 2025
🪶 Abstract submission: 15 Jan 2026
📄 Satellite programmes & speakers: 15 Jan 2026
📦 Sponsor material delivery at venue: 20 Mar 2026
Stay tuned for updates -> 🔗 baveno8.org

#LiverTwitter

Towards a cure for hepatitis B A new clinical trial is testing a vaccine that could be the answer for people living with chronic hepatitis B infection.,,,European...

💬 Proud to be featured by #CORDIS! They spotlight #TherVacB's clinical trial as a key step toward a functional cure for chronic #hepB.
🎥 Our awareness videos with @dsolve.bsky.social explain diagnosis, co-infection & care.
🔗 link.europa.eu/QMFx3J

#HBV #HDV #LiverSky #HepSky #LiverTwitter

Join us in VALENCIA for the 3rd International Workshop on LIVER and GUT FIBROSIS, 16-17 Oct. Registration closes 6th Oct
eventos.adeit.es/go/3rdFibros... #LiverGutFibrosis25 #livertwitter #IBD #fibrosis @ciberisciii.bsky.social @myueg.bsky.social @ibddoctor.bsky.social @crohnscolitisfdn.bsky.social

The FDA accepted Echosense’ Letter of Intent for the qualification of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography (FibroScan) as a reasonably likely surrogate endpoint in clinical trials for MASH.

Learn more: www.hcplive.com/view...

#LiverTwitter

Register now for this specialist workshop on LIVER and GUT FIBROSIS, taking place on 16-17 Oct, in the beautiful city of VALENCIA. Check out the programme here: eventos.adeit.es/130936/secti... #fibrosisvlc #LiverGutFibrosis25 #livertwitter #IBD

Semaglutide 2.4 mg has received approval for MASH.

In April, #DiabetesDialogue recorded a special edition episode on the ESSENCE trial with Dr. Arun Sanyal.

www.hcplive.com/view/diabete...

#Hepatology #LiverTwitter

Send your abstract in before 31st August! Travel grants -courtesy of PharmaNestInc - will be awarded to stand out submissions eventos.adeit.es/go/3rdFibrosis #fibrosisvlc #LiverGutFibrosis25 #livertwitter #IBD @ciberisciii.bsky.social l‬

6.10.3 - Expert: Tim Jobson on Using Basic Data and Analytics to Identify At-Risk Patients Podcast Episode · Surfing the MASH Tsunami · S6, E10 Bonus · 37m

@timjobson.bsky.social joined the Surfing the MASH Tsunami podcast with Roger Green & Louise Campbell to discuss hepatoSIGHT™ and how it’s speeding better treatments to patients. A must-listen for #ClinicalTrials & #LiverDisease #LiverTwitter

podcasts.apple.com/gb/podcast/6...

Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from ... The combined efficacy, safety, and tolerability data with ervogastat supports continued investigation for its use in MASH. Larger and longer trials are needed to further assess ervogastat and ervogast...

Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis: results from the phase 2, randomised MIRNA study

www.thelancet.com/journals/lan...

#LiverTwitter #MedTwitter

Your input matters! Now through August 11, #AASLD is accepting public comments for the proposed recommendations in the AASLD Practice Guideline on Adult #LiverTransplantation: Candidate Evaluation. Submit your comments today! bit.ly/4o7MkCx #LiverTwitter

Protons, Photons, & everything in between. Join us on July 15th as we breakdown NRG-GI003 comparing protons & photons for hepatocellular carcinoma with study PI, Dr. Ted Hong. Listen to older episodes and find where to follow at nrgoncology.org/Podcast #LiverTwitter #LiverX #HCC

Creation of a new VA liver transplantation center increased ... : Liver Transplantation An abstract is unavailable. This article is available as a PDF only.

Creation of a new VA liver transplantation center increased access and retained care within veterans health administration

Read the brief report 👇🏼
#livertwitter
#liversky
@aasldnews.bsky.social
@livertransplant.bsky.social
journals.lww.com/lt/citation/...

Successful HCV Treatment with DAAs Linked to Lower Extrahepatic Manifestation Risk Successful HCV treatment with DAAs was associated with reduced risks of CKD, stroke, major adverse cardiac events, and neurocognitive disorders.

Successful #HCV treatment with DAAs is associated with a reduced risk of several extrahepatic manifestations, including chronic kidney disease, stroke, major adverse cardiac events, and neurocognitive disorders.

Learn more: www.hcplive.com/view...

#LiverTwitter

Excited to see what BlueSky can offer in the #LiverTwitter field.

I hope to join the discussion on #WilsonDisease and share our results here going forward.

🏆 Community Award to @docberza.bsky.social (Bern, Switzerland) at #EASL2025

💬 Beautiful and emotional intro by @RodriguesSu24
🙏 So proud to have you in @bavenocoop.bsky.social
— well deserved!

#LiverTwitter

Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial) There is no evidence of a difference between carvedilol 12.5 mg daily and VBL in the primary prevention of variceal bleeding in patients with cirrhosis and medium-to large-sized oesophageal varices. ....

🔗 Full paper: doi.org/10.1111/apt....

📝 Editorial by @reibergerthomas.bsky.social and Benedikt Simbrunner:
onlinelibrary.wiley.com/doi/epdf/10....

#LiverTwitter

Engage with our panellists and ask your burning questions about CCA diagnostic tests. Join the conversation on our virtual platform: rb.gy/s6p2aw

#AMMF2025 #Livertwitter #cholangiocarcinoma

Exhibitor booths are not usually meeting highlights but this is an exception. Kudos to @boehringerglobal.bsky.social
on this artistic rendition on the theme of liver health and disease @easlnews.bsky.social #EASLCongress
#livertwitter

#LIVERAIM networking session has started at track hub8!
Join us and learn how #biomarkers of #liverfibrosis can reshape the future of Hepatology
#livertwitter #EASLCongress @aleksanderkrag.bsky.social @ihieurope.bsky.social @salvatore-piano.bsky.social @easlnews.bsky.social @IHI